1041026-71-4

Basic information

• Product Name: tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate
• Synonyms: tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate;2,6-Diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester heMioxylate;2,6-Diazaspiro[3.3]heptane-2-carboxylic acid, 1,1-diMethylethyl ester, ethanedioate (2:1);1-Boc-2,6-diazaspiro[3.3]heptane heMioxalate, 97%;tert-Butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate, hemioxalate salt;2,6-Diazaspiro[3.3]heptane-2-carboxylic acid, 1,1-diMethylethyl ester, heMioxalate;tert-Butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate(2:1);2,6-Diazaspiro[3.3]heptane-2-carboxylic acid 1,1-dimethylethyl ester ethanedioate
• CAS NO: 1041026-71-4
• Molecular Formula: C12H20N2O6
• Molecular Weight: 288.297
• Mol File: 1041026-71-4.mol

Chemical Properties

• Melting Point: 206-209℃
• Appearance: /Solid
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Sonicated)
• Water Solubility: Slightly soluble in water.
• Stability: Hygroscopic
• CAS DataBase Reference: tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate(1041026-71-4)
• EPA Substance Registry System: tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate(1041026-71-4)

Safety Data

• Hazardous Substances Data: 1041026-71-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate is used as an intermediate for the synthesis of pharmaceutical compounds. Its role is essential in the development of new drugs and therapies.
Used in the Preparation of CDK Inhibitors:
In the field of medicinal chemistry, tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate is used as a key component in the synthesis of pyrimidine derivatives and related heterocycles. These compounds act as CDK inhibitors, which are vital for the treatment of various diseases by regulating cell cycle progression and preventing uncontrolled cell growth.
Used in Drug Development:
The compound is also utilized in drug development, where it contributes to the creation of novel therapeutic agents. Its unique chemical properties make it a valuable asset in the design and synthesis of new pharmaceuticals with potential applications in treating a wide range of medical conditions.

Preparation

Synthesis of 2,6-Diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester hemioxylate: Take a 500mL single-necked bottle, add 6-toluenesulfonyl-2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (7g, 20mmol), dissolve in methanol (200mL), add magnesium chips (3.84 g) g, 0.16 mol, 8 equiv) and stirred at room temperature. The reaction solution gradually turned into a white viscous state with the dissolution of the magnesium scraps, and TLC showed that the reaction of the raw materials was completed. The solvent was removed by rotary evaporation, ether (150 mL) was added, stirred at room temperature for 1 h, filtered through celite, the filtrate was dried over anhydrous sodium sulfate, and an ethanol solution (3 mL) of anhydrous oxalic acid (0.89 g, 9.9 mmol, 0.5 equiv) was added dropwise, A white precipitate appeared immediately, which was filtered under reduced pressure to give 3.2 g of a colorless solid, 82%.

InChI:InChI=1S/2C10H18N2O2.C2H2O4/c2*1-9(2,3)14-8(13)12-6-10(7-12)4-11-5-10;3-1(4)2(5)6/h2*11H,4-7H2,1-3H3;(H,3,4)(H,5,6)

Upstream product

• 1041026-70-3 2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester hemioxylate 
• 144-62-7 oxalic acid 
• 1150618-17-9 di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1041026-64-5 2-benzyl-6-(p-toluenesulfonyl)-2,6-diazaspiro[3.3]heptane 
• 26096-30-0 N-benzyl-3,3-bis-(hydroxymethyl)-azetidine 
• 1041026-67-8 tert-butyl 6-(p-toluenesulfonyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate 

Downstream Products

• 1349875-71-3 tert-butyl 6-acetyl-2,6-diazaspiro[3.3]heptane-2-carboxylate 
• 1333215-20-5 tert-butyl 6-(4-fluorophenyl)-2,6-diazaspiro[3,3]heptane-2-carboxylate 
• 1333215-19-2 2-(4-fluorophenyl)-2,6-diazaspiro[3,3]heptane 

Relevant articles and documents

1-azaspirocycle compound, and preparation method and applications thereof

The invention discloses a 1-azaspirocycle compound, and preparation method and applications thereof, and belongs to the field of pharmaceutical chemistry. The 1-azaspirocycle compound with a structurerepresented by formula I, or a pharmaceutically acceptable salt or a stereisomer or a solvate or a prodrug thereof is capable of realzing combination with Autotaxin, can be taken as an Autotaxin inhibitor, and can be used for prevention and treatment of diseases with Autotaxin expression increasing pathological characteristics such as cancer and fibrosis diseases especially pulmonary fibrosis andhepatic fibrosis, metabolic diseases, myelodysplastic syndrome, cardiovascular diseases, autoimmune diseases, inflammation, neurological diseasses, or pain. Compared with single component inhibitors,the 1-azaspirocycle compound and the derivatives possesses following advantages: blocking and interfacing at the upsteam of a plurality of key signal channels are realized, tumor cell growth and transfer are relieved or dalyed, early caused drug resistance is avoided, and novel means are provided for treatment of tumor cells.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.

HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

2,6-Diazaspiro[3.3]heptanes: Synthesis and application in Pd-catalyzed aryl amination reactions

(Chemical Equation Presented) A concise and scalable synthesis of a 2,6-diazaspiro[3.3]heptane building block is reported. The usefulness of this structural surrogate of piperazine is shown in arene amination reactions yielding a variety of W-Boc-W-aryl-2,6-diazaspiro[3.3]heptanes.